HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic pruritus: a paraneoplastic sign.

Abstract
Chronic itch could be a presenting sign of malignancy. Pruritus of lymphoma is the common prototype of paraneoplastic itch and can precede other clinical signs by weeks and months. Paraneoplastic pruritus has also been associated with solid tumors and is an important clinical symptom in paraneoplastic skin diseases such as erythroderma, Grovers disease, malignant acanthosis nigricans, generalized granuloma annulare, Bazex syndrome, and dermatomyositis. In any case with high index of suspicion a thorough work-up is required. This review highlights the association between itch and malignancy and presents new findings related to pathophysiological mechanisms and the treatment of itch associated with malignancy. Combinative therapies reducing itch sensitization and transmission using selective serotonin and neuroepinephrine reuptake inhibitors, Kappa opioids, and neuroleptics are of prime importance in reducing this bothersome symptom.
AuthorsGil Yosipovitch
JournalDermatologic therapy (Dermatol Ther) Vol. 23 Issue 6 Pg. 590-6 ( 2010) ISSN: 1529-8019 [Electronic] United States
PMID21054705 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Copyright© 2010 Wiley Periodicals, Inc.
Chemical References
  • Antipruritics
Topics
  • Antipruritics (therapeutic use)
  • Chronic Disease
  • Humans
  • Paraneoplastic Syndromes (drug therapy, epidemiology, etiology, physiopathology)
  • Pruritus (drug therapy, epidemiology, etiology, physiopathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: